Edition:
India

Sarepta Therapeutics Inc (SRPT.OQ)

SRPT.OQ on NASDAQ Stock Exchange Global Select Market

56.22USD
22 Nov 2017
Change (% chg)

-- (--)
Prev Close
$56.22
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
718,360
52-wk High
$57.50
52-wk Low
$26.26

Latest Key Developments (Source: Significant Developments)

Sarepta Therapeutics prices $475 million of convertible senior notes due 2024
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Sarepta Therapeutics Inc :Sarepta Therapeutics prices $475 million of convertible senior notes due 2024.Sarepta Therapeutics-‍priced $475 million aggregate principal amount of convertible senior unsecured notes that will mature on November 15, 2024​.Sarepta Therapeutics - ‍notes will bear cash interest at a rate of 1.50%, payable on May 15 and November 15 of each year, beginning on May 15, 2018​.  Full Article

Sarepta Therapeutics announces proposed offering of $375 mln of convertible senior notes
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Sarepta Therapeutics Inc :Sarepta Therapeutics announces proposed offering of $375 million of convertible senior notes due 2024.Sarepta Therapeutics Inc - ‍Chief Executive Officer indicates interest in purchasing $2 million of shares of Sarepta's common stock​.Sarepta - ‍intends to use a portion of net proceeds from offering to pay cost of certain capped call transactions​.Sarepta - ‍purchase price/share of stock bought by ingram expected to equal closing price/share of co's stock on date of pricing of offering​.  Full Article

Sarepta Therapeutics reports FDA clearance of IND for co's ppmo exon 51 candidate, srp-5051
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Sarepta Therapeutics Inc ::Sarepta Therapeutics announces FDA clearance of IND for the company's ppmo exon 51 candidate, srp-5051.Sarepta Therapeutics Inc - will immediately initiate its phase 1/2a clinical trial and begin screening patients with dmd amenable to skipping exon 51​.  Full Article

Sarepta Therapeutics says FDA clears gene therapy IND application
Friday, 3 Nov 2017 

Nov 3 (Reuters) - Sarepta Therapeutics Inc -:Sarepta Therapeutics and Nationwide Children’S Hospital announce U.S. Food And Drug Administration (FDA) clearance of the IND application for the GALGT2 gene therapy program.Sarepta Therapeutics- ‍IND application for GALGT2 gene therapy program was cleared by FDA​.Sarepta Therapeutics - Nationwide Children's is on track to initiate Phase 1/2A clinical trial in individuals with DMD by year-end 2017 ​.  Full Article

Sarepta Therapeutics signs exclusive global collaboration with Duke University
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Sarepta Therapeutics Inc :Sarepta Therapeutics signs exclusive global collaboration with Duke University for Gene Editing CRISPR/CAS9 technology to develop new treatments for Duchenne Muscular Dystrophy (DMD).Sarepta Therapeutics Inc - ‍financial terms of agreement have not been disclosed​.  Full Article

Sarepta Therapeutics sees FY17 revenue $150 mln to $155 mln
Thursday, 26 Oct 2017 

Oct 25 (Reuters) - Sarepta Therapeutics Inc ::Sarepta Therapeutics announces third quarter 2017 financial results and recent corporate developments.Q3 non-GAAP loss per share $0.20.Q3 earnings per share view $-0.85 -- Thomson Reuters I/B/E/S.Q3 GAAP loss per share $0.78.Sees FY 2017 revenue $150 million to $155 million.Q3 revenue $46 million versus I/B/E/S view $40.8 million.Sarepta Therapeutics Inc - ‍raises annual 2017 revenue guidance to between $150 million and $155 million​.  Full Article

UnitedHealth spokesman confirms plan to cover Sarepta's Exondys 51
Friday, 7 Oct 2016 

UnitedHealth Group Inc : UnitedHealth spokesman confirms plans to cover Sarepta Therapeutics Inc's muscular dystrophy drug Exondys 51. (Reporting by Caroline Humer) ((caroline.humer@thomsonreuters.com;)).  Full Article

Summit's agreement with Sarepta also contains a standstill provision
Tuesday, 4 Oct 2016 

Summit Therapeutics Plc : Collaboration agreement with Sarepta also contains a standstill provision - SEC filing .Summit Therapeutics - Believes cash, cash equivalents, certain upfront payments from Sarepta collaboration to be sufficient to fund expenses through 2018.  Full Article

Sarepta and Summit enter into agreement for European rights to utrophin modulator pipeline
Tuesday, 4 Oct 2016 

Summit Therapeutics Plc : Summit receives $40 million upfront, with potential future ezutromid-related milestone payments totalling up to $522 million plus royalties . Sarepta also receives option for Latin American rights . As part of agreement, Sarepta also obtains an option to license latin american rights to Summit's utrophin modulator pipeline . If Sarepta elects to exercise option for Latin American rights, co would be entitled to additional fees, milestones and royalties . Sarepta and Summit to share research and development costs . Sarepta also receives option for Latin American rights . Sarepta Therapeutics and summit enter into exclusive license and collaboration agreement for european rights to summit’s utrophin modulator pipeline for the treatment of duchenne muscular dystrophy .Sarepta, co will share specified utrophin modulator-related research and development costs at a 45/55 pct split, respectively.  Full Article

Catabasis Pharma & Sarepta Therapeutics to collaborate in Duchenne muscular dystrophy
Thursday, 29 Sep 2016 

Catabasis Pharmaceuticals Inc : Collaboration to study exon skipping treatment by Sarepta with co's oral NF-KB inhibition treatment in mouse model of DMD . Catabasis Pharmaceuticals and Sarepta Therapeutics announce a joint research collaboration in Duchenne muscular dystrophy .Collaboration to explore a combination drug treatment approach for Duchenne muscular dystrophy.  Full Article

Photo

Health insurer Anthem eases restrictions on Sarepta's Duchenne treatment

NEW YORK Health insurer Anthem Inc has eased access to Sarepta Therapeutics' treatment for Duchenne muscular dystrophy, and on Thursday changed its reimbursement policy on its website to "medically necessary."